問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳嘉夆

Recruiting

List

31Cases

2025-11-01 - 2027-10-11

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-01-16 - 2028-10-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-12-01 - 2025-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-12-01 - 2025-12-31

Phase IV

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

2024-09-01 - 2030-10-28

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-03-01 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-05-01 - 2028-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-06-30 - 2024-09-02

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-06-01 - 2022-01-31

Phase III

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    Baricitinib

Participate Sites
9Sites

Recruiting9Sites

2018-06-29 - 2022-06-30

Phase II

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    BMS-986165

Participate Sites
8Sites

Recruiting8Sites

張棋楨
Taipei Medical University Hospital

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB